LiFe-saving tissue therapeutics

Making cell therapies implantable

Cellbricks Therapeutics develops implantable tissue therapeutics to help patients live longer, healthier lives, leveraging its proprietary biofabrication platform and 10 years of tissue engineering expertise.

The Problem We Solve

Current injectable cell therapies do not achieve sustainable efficacy due to a lack of engraftment in the patient.

Solution: Implantable tissue therapeutics

Sustainable effect at the target tissue
Vascularised
Immune compatible

Tissue therapeutics represent a new category of regenerative medicine by making cell therapies implantable, resulting in stable engraftment and effective treatment.

Tissue ThERAPEUTIC PROGRAMS

Cellbricks Therapeutics develops biofabricated tissue therapeutics that are biologically functional, immune-compatible, and optimized for surgical implantation.

Cellbricks Figure - Therapeutic Programs

We have two therapeutic programs with the potential to redefine treatment for diseases that are currently incurable.

Technology

Cellbricks Therapeutics combines therapeutic cells with tailor-made biomaterials via its proprietary biofabrication platform centered around light-based bioprinting to create implantable tissue therapeutics.

Therapeutic Cells

Multiple types

biomaterials

Liquid extracellular matrix (including recombinant production)

3D-Bioprinter

The design and reproducible imprinting of cells using light, at organ sized volumes, with vasculature, within minutes.

tissue

Immune compatible vascularized organ tissue at industrial scale.

Advantages of Cellbricks Therapeutics’ light-based multi-material 3D-bioprinting technology:

Very cell-friendly

Multiple cell types

High speed and resolution

Large volumES

Cellbricks Therapeutics reconciles the most important requirements for industrial production of vascularized, functional, complex and implantable human tissue.

Team and Career

Our team brings together scientific and operational expertise with the mission to bring live-saving tissue therapeutics into the clinic enabling patients to live longer and healthier lives.

Leadership

DR. SIMON MACKENZIE

Co-CEO

Former CEO at RegenHU; CBO at Axol Bioscience; Director at Kyorin Pharmaceutical Co.

25 years building and leading biotech and pharma therapeutics teams across US, EU, Asia; Expertise in iPSCs, bioprinting, pharma partnering; PhD biochemistry with 26 publications and patent.

Alexander Leutner

Co-CEO

Founded, scaled & exited previous deep-tech start-up Apodius to Hexagon

12 years building and leading teams in start-up and corporate settings, deal-making with key accounts and top-level management (incl. M&A process), MSc mechanical engineering.

Alexander Thomas

Therapeutic Program Leader

Cellbricks founder;
PhD on bioprinted vasculature

10 years experience of 3D-bioprinting & tissue engineering; Expertise in vasculature and biomaterials; 10 publications.

Dr. Alicia Ruppelt

Therapeutic Program Leader

Former R&D liver engineer at LifeTec Group; Researcher at Merck

6 years experience of 3D-bioprinting & tissue engineering. Scientific and managerial industry expertise; PhD biotechnology, 4 publications.

Dr. Tobias LAM

CTO

Cellbricks founder;
Created bioprinting technology

10 years experience of 3D-bioprinting and biomaterial formulation. Built the first, and continues to develop, the Cellbricks 3D Bioprinting technology; PhD biotechnology, 12 publications.

Jenny Schkoldow

Operations Manager

Former Senior Associate Research Scientist at Bayer

20 years of pharma R&D expertise; BSc molecular biology.

We are an interdisciplinary team of entrepreneurs, engineers, chemists and biologists driven by excellence and proactive spirit. With every new team member, we add more passion and expertise to our mission. Check our open roles and see where you fit.

-> Unfortunately, at the moment, we don't have any job vacancies.